University of Chicago-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2019

  1. Cost of achieving hba1c and weight loss treatment targets with ideglira vs insulin glargine u100 plus insulin aspart in the usa

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 271-282

  2. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy

    Diabetes, Obesity and Metabolism, Vol. 21, Núm. 12, pp. 2643-2650

2018

  1. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The dual VII randomized clinical trial

    Diabetes Care, Vol. 41, Núm. 5, pp. 1009-1016